What are the three prescription streams, and how do they differ?
They differ in who prescribes, what form the prescription takes and what the pharmacy must verify. Handle them as one undifferentiated pile and you will eventually dispense something you should have questioned. The dispensing law itself lives in our Schedule 2 remote dispensing guide; this is the operational layer on top.
| Stream | Prescriber | Form | The pharmacy's specific checks |
|---|---|---|---|
| Shared care | Patient's GP, prescribing under a shared care agreement after specialist stabilisation | NHS FP10 or EPS | Standard Schedule 2 checks; continuity awareness at dose changes, which should trace to a specialist review |
| Right to Choose provider | Specialist prescriber at an NHS-contracted independent provider, typically during titration or where the GP has declined shared care | NHS prescription issued by the provider | Standard Schedule 2 checks plus provider and prescriber familiarity, since the prescriber is usually remote and previously unknown to the pharmacy |
| Private clinic | Specialist prescriber at a private provider | FP10PCD with the prescriber's six-digit private CD identifier | Full private CD formalities: designated form, identifier present, prescriber verified, monthly NHSBSA submission |
Two constants apply across all three streams. First, every one of these prescriptions is Schedule 2: 28 days' validity from the appropriate date, no repeats, owings dead at 28 days and 30-day quantities as good practice, whichever stream it arrived by. Second, every unfamiliar prescriber gets verified before the first dispensing, and the check gets recorded. That means registration confirmed, and for private prescriptions the identifier treated as a hard gate. The verification playbook, including standing verification for clinics that send regular volume, is the same one we set out for the CBPM workflow. Schedule 2 discipline does not care about the diagnosis.
The streams also move. A typical patient journey runs private or Right to Choose titration first, then transfer to GP shared care. So the same patient's prescriptions change form mid-relationship. Track which stream each ADHD patient is currently in and you give yourself an early warning system for the failure mode covered next.
What should the pharmacy do when shared care breaks down?
Signpost fast, hold the record straight and never improvise supply. A shared care breakdown is a prescribing gap the pharmacy cannot lawfully fill. The scenario is now routine: the GP declines the shared care agreement, or withdraws from one, and the patient arrives at the counter mid-treatment with no active prescriber. GP hesitancy is real and partly rational. It rests on workload, Schedule 2 prescribing risk and confidence in remote providers' records. And the 2026 scrutiny of the sector, covered in our analysis of the CQC changes and prescribing warnings, has not helped acceptance rates.
The pharmacy's playbook has four moves. First, clarity about the boundary. No emergency supply exists for Schedule 2 medicines, so sympathy never becomes supply. The team should be able to say so kindly and identically every time. Second, signposting with precision. The patient's route back to medicine is the provider who diagnosed them. Most Right to Choose and private providers will continue prescribing directly where a GP declines shared care. A pharmacy that notes which provider each ADHD patient came through can point them at the right door in one conversation. Third, early warning. The pharmacy often sees the breakdown first, as a shared-care patient whose GP prescription simply stops. Flagging it to the patient two weeks before they run out is worth more than anything anyone can do at the counter on day zero. Fourth, records. Log the interaction, the advice given and the signposting. A patient in a prescribing gap is exactly the situation that later gets reviewed.
What the pharmacy should not do is arbitrate. Whether the GP was right to decline, whether the provider's titration records were adequate, whether shared care should resume — these are prescriber-to-prescriber questions. The pharmacy's value is being the calm, accurate node in the middle while they resolve it.
What can a pharmacy actually do in the ADHD medicines shortage?
Less than patients hope, and more than nothing. The honest version of the list is the one worth training the whole team on.
Pharmacists must dispense in accordance with the prescription. They cannot substitute a different product, strength or formulation without either a new prescription or a valid serious shortage protocol. SSPs are Department of Health and Social Care instruments that permit defined deviations during confirmed shortages. But for Schedule 2 controlled drugs they are available only in very restricted circumstances, and the government confirmed in January 2025 that it had no plans to issue SSPs for methylphenidate or other ADHD medicines. Emergency supply at patient request does not apply to Schedule 2 at all. The net position: for ADHD stimulants, every change of any kind routes through a prescriber.
Inside those walls, the pharmacy still has real moves:
Stock intelligence, offered early. Check what strengths, brands and equivalent lines are actually obtainable before the patient or prescriber wastes a week — then volunteer it. A message to the prescriber saying "cannot source X, can source Y and Z this week" converts a dead prescription into a same-day reissue. Dose equivalences between products are the prescriber's decision, never the pharmacy's suggestion to the patient. But availability is the pharmacy's information to give.
28-day discipline as patient protection. Do not accept a prescription into a silent queue against stock that may not come. Make the shortfall call on day one. Return the decision to the prescriber while the prescription still has life in it, exactly as the owings rule demands.
Sourcing breadth. Second-line wholesalers, brand-for-generic availability differences and strength-splitting options (two lower-strength packs against a prescription written for them) are all legitimate pharmacy craft. Apply them within dispense-as-written limits.
Reorder coaching. Every ADHD patient should hear, at every handover during the shortage, that reordering starts seven to ten days early. The one flexibility in this system is time, and only the patient controls it.
Honest escalation. When a line is nationally gone, say so in writing, to the prescriber and patient at once. That way the switching conversation starts immediately, not after three more hopeful phone calls.
How should the pharmacy manage the patient relationship through all this?
By being the one point in the system that is consistent, informed and never falsely reassuring. ADHD patients in 2026 are navigating multi-year waits, shared care refusals and stock failures all at once, and the pharmacy is the part of the system they see most often. Three practices carry most of the weight.
One story, whole team. The rules in this guide — no emergency supply, no substitution, prescriber-routed changes — are counterintuitive. Half-explained, they sound like unhelpfulness. So script the explanations and train everyone on them.
"A patient told 'the law does not let any pharmacy do that, and here is what actually will work' leaves with a plan. A patient told 'we can't do that' leaves with a grievance."
Continuity notes. Keep the patient's stream, provider, usual product and shortage history visible on the record, so any team member can have an informed conversation. This is exactly the kind of longitudinal, custom-field record a modern PMR should carry. It turns the fifth shortage conversation from a restart into a continuation.
Sensitivity at the counter. These are patients whose functioning may depend on the medicine that is out of stock. They are collecting a Schedule 2 drug that carries stigma, sometimes for their children. The identity checks and signature formalities are legal requirements — and delivering them with warmth rather than suspicion is free. Note also who lawfully collects for a child or young person, and settle the parent-and-carer handling in the SOP rather than negotiating it at the counter.
There is a commercial line under the service one. Pharmacies that handle this well are becoming the recommended pharmacy of ADHD providers, and the fixed point for patients who move between prescribers. In a category generating a fresh Schedule 2 dispensing every month per patient, being good at the hard parts is the growth strategy. For pharmacies serving clinics at volume, the systems that make it scale are covered in our forthcoming piece on the IT gap in ADHD and titration services, and the deeper partnership structure in the forthcoming clinic-plus-pharmacy model.
Key takeaways
- ADHD prescriptions arrive by three streams — shared care FP10s, Right to Choose provider prescriptions and private FP10PCDs. Each carries distinct verification duties over the same Schedule 2 core rules.
- Track which stream each ADHD patient is in. Patients move between streams, and the transitions are where prescribing gaps open.
- When shared care breaks down, the pharmacy signposts to the originating provider, warns early, records the interaction and never improvises supply.
- In the shortage, the constraint stack is absolute. Dispense as written. No substitution without a new prescription. SSPs are effectively unavailable for these Schedule 2 lines, per the government's own January 2025 position. No emergency supply.
- The pharmacy's real shortage moves: stock intelligence volunteered to prescribers, day-one shortfall decisions inside the 28-day window, sourcing breadth and relentless reorder coaching.
- Script the explanations and train the whole team on one story. The rules sound like unhelpfulness when half-told.
- Handled well, ADHD dispensing is a monthly-cycle, high-loyalty service line. The pharmacies mastering it are becoming the sector's preferred dispensing partners.
Sources and further reading
FAQs
Continuity is the service.
The continuity this guide keeps demanding — which stream each patient is in, their provider, their product history, their monitoring notes — is exactly what Dataforge PMR holds in one place. It gives you assessments with custom fields tracked and updated over time, notes and prescriber records on the patient, reminders driving the monthly cycle and recalls, and dispensing with label printing. The controlled drugs register module is scheduled for release at the end of 2026. Our publisher also writes the SOPs that turn this playbook into inspection-ready process. If ADHD dispensing is becoming a serious line for your pharmacy, book a 30-minute call.
Book a call